Literature DB >> 22863758

Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD.

Davinder S Garcha1, Sarah J Thurston, Anant R C Patel, Alexander J Mackay, James J P Goldring, Gavin C Donaldson, Timothy D McHugh, Jadwiga A Wedzicha.   

Abstract

BACKGROUND: Prevalence and load of airway bacteria in stable and exacerbated chronic obstructive pulmonary disease (COPD) has been previously studied using microbiological culture. Molecular techniques, such as quantitative PCR (qPCR), may be more informative.
METHODS: In this study, 373 sputum samples from 134 COPD outpatients were assessed for prevalence and load of typical airway bacteria (Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis) by multiplex qPCR, with 176 samples analysed for atypical bacteria. Paired stable and exacerbation typical bacteria data were compared in 52 patients. We compared routine culture with qPCR in 177/373 samples.
RESULTS: Typical bacteria were more prevalent in exacerbation than stable-state paired samples: 30/52 (57.7%) vs. 14/52 (26.9%); p=0.001. In patients who were bacteria-positive at both time points, mean (±1 SEM) load was significantly higher at exacerbation than stable state (108.5(±0.3) vs. 107.2(±0.5) cfu/ml), constituting a 20-fold increase (p=0.011). qPCR was more discriminatory at detecting typical bacteria than microbiological culture (prevalence 59.3% vs. 24.3%; p<0.001). At stable state, higher airway bacterial load correlated with more severe airflow limitation (FEV(1)%predicted) (r=-0.299; p=0.033) and higher inhaled corticosteroid dosage (r=0.382; p=0.008). Mean C-reactive protein was higher in bacterial-associated exacerbations (35.0 Vs 25.1 mg/L; p=0.032).
CONCLUSIONS: Airway bacterial prevalence and load increase at COPD exacerbations and are an aetiological factor. qPCR is more discriminatory than culture, identifying higher airway bacterial prevalence. Exacerbations associated with bacterial detection showed a higher mean C-reactive protein level. In the stable state, airway bacterial load is related to more severe airflow limitation and higher inhaled corticosteroid dosage used.

Entities:  

Mesh:

Year:  2012        PMID: 22863758     DOI: 10.1136/thoraxjnl-2012-201924

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  89 in total

1.  Repeated Exposure to Streptococcus pneumoniae Exacerbates Chronic Obstructive Pulmonary Disease.

Authors:  Xuxu Gou; Qiao Zhang; Sunil More; Gayan Bamunuarachchi; Yurong Liang; Faizan Haider Khan; Rachel Maranville; Emily Zuniga; Changzheng Wang; Lin Liu
Journal:  Am J Pathol       Date:  2019-06-18       Impact factor: 4.307

2.  Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease.

Authors:  Gavin C Donaldson; Martin Law; Beverly Kowlessar; Richa Singh; Simon E Brill; James P Allinson; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2015-10-15       Impact factor: 21.405

Review 3.  Microbial uptake by the respiratory epithelium: outcomes for host and pathogen.

Authors:  Margherita Bertuzzi; Gemma E Hayes; Elaine M Bignell
Journal:  FEMS Microbiol Rev       Date:  2019-03-01       Impact factor: 16.408

Review 4.  DAMPs activating innate and adaptive immune responses in COPD.

Authors:  S D Pouwels; I H Heijink; N H T ten Hacken; P Vandenabeele; D V Krysko; M C Nawijn; A J M van Oosterhout
Journal:  Mucosal Immunol       Date:  2013-10-23       Impact factor: 7.313

Review 5.  Inhaled corticosteroids and the increased risk of pneumonia: what's new? A 2015 updated review.

Authors:  Hernan Iannella; Carlos Luna; Grant Waterer
Journal:  Ther Adv Respir Dis       Date:  2016-02-18       Impact factor: 4.031

6.  Community-acquired pneumonia in patients with chronic obstructive pulmonary disease.

Authors:  Aykut Cilli
Journal:  Curr Infect Dis Rep       Date:  2015-01       Impact factor: 3.725

7.  Phase variation and host immunity against high molecular weight (HMW) adhesins shape population dynamics of nontypeable Haemophilus influenzae within human hosts.

Authors:  Gregg S Davis; Simeone Marino; Carl F Marrs; Janet R Gilsdorf; Suzanne Dawid; Denise E Kirschner
Journal:  J Theor Biol       Date:  2014-04-18       Impact factor: 2.691

8.  C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT.

Authors:  Nick A Francis; David Gillespie; Patrick White; Janine Bates; Rachel Lowe; Bernadette Sewell; Rhiannon Phillips; Helen Stanton; Nigel Kirby; Mandy Wootton; Emma Thomas-Jones; Kerenza Hood; Carl Llor; Jochen Cals; Hasse Melbye; Gurudutt Naik; Micaela Gal; Deborah Fitzsimmons; Mohammed Fasihul Alam; Evgenia Riga; Ann Cochrane; Christopher C Butler
Journal:  Health Technol Assess       Date:  2020-03       Impact factor: 4.014

9.  Activity, severity and impact of respiratory disease in primary antibody deficiency syndromes.

Authors:  John R Hurst; Sarita Workman; Davinder S Garcha; Suranjith L Seneviratne; Jamanda A Haddock; Bodo Grimbacher
Journal:  J Clin Immunol       Date:  2013-10-18       Impact factor: 8.317

10.  Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence.

Authors:  David de la Rosa; Miguel-Angel Martínez-Garcia; Casilda Olveira; Rosa Girón; Luis Máiz; Concepción Prados
Journal:  Chron Respir Dis       Date:  2016-07-07       Impact factor: 2.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.